Personalized Integrated Alcohol and Sexual Assault Prevention Among College Students

Heavy episodic drinking and sexual assault are problematic on college campuses. This study includes a randomized controlled trial of Positive Change (+Change), an integrated alcohol and sexual assault prevention program, compared to an attention-matched control condition across two universities in reducing alcohol use, sexual assault victimization, sexual assault perpetration, and increasing sexual assault bystander intervention. This study will also test the efficacy of +Change plus Booster session, an identical version of +Change delivered 6 months after the baseline, compared to +Change alone in long-term reductions in alcohol use, sexual assault victimization, sexual assault perpetration, and increases in sexual assault bystander intervention. This research is the next step of a NIAAA-funded planning grant (R34AA025691).

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • behavioral: Positive Change (+Change)
  • behavioral: A healthy lifestyles attention control
  • behavioral: Positive Change (+Change) Plus Booster

Eligibility


Inclusion Criteria:

   - 18-25 years old

   - Current student at university of study

   - Valid email address at university of study

   - Endorse engaging in heavy episodic drinking at least once in the past month on the
   screening survey

Exclusion Criteria:

• There are no exclusion criteria other than not meeting inclusion criteria

Ages Eligible for Study

18 Years - 25 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting

Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation,  mobile application development, and pharmaceutical trials.  

Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.